LitCovid-sentences  

PMC:7396557 / 99830-107145 JSONTXT 11 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T752 0-26 Sentence denotes Discussion and Conclusions
T753 27-117 Sentence denotes It is a critical moment in the battle to defeat the current outbreak of novel coronavirus.
T754 118-214 Sentence denotes For this specific indication, rapid performance of TCM can contribute as an alternative measure.
T755 215-306 Sentence denotes TCM can effectively prevent the disease from transforming into severe and critical disease.
T756 307-455 Sentence denotes In severe cases, TCM has won time for recovery by improving symptoms (The State Council Information Office of the People’s Republic of China, 2020).
T757 456-659 Sentence denotes Treatment practice for COVID-19 has shown that early intervention with TCM is an important method to improve cure rate, shorten the course of disease, delay disease progression and reduce mortality rate.
T758 660-790 Sentence denotes For example, the total response rate of Qingfei Paidu Decoction was more than 90% in Shanxi and Hebei provinces (He et al., 2020).
T759 791-949 Sentence denotes CPMs have played an important role in preventing and treating epidemic diseases in China because they are convenient to use, easily stored and cost-effective.
T760 950-1090 Sentence denotes The positive role of CPMs has been emphasized in the “Diagnosis and Treatment of COVID-19 (Trial Version 7)” and other therapeutic regimens.
T761 1091-1252 Sentence denotes During the medical observation period and early stage of COVID-19, HXZQC, LHQWC, SFJDC, and JHQGG can be selected according to different clinical manifestations.
T762 1253-1320 Sentence denotes At the same time, they can also promote immunity against the virus.
T763 1321-1438 Sentence denotes For severe and critical disease, the choice shall be made according to different syndromes during clinical treatment.
T764 1439-1767 Sentence denotes For viral infections combined with mild bacterial infections, XYPI and TRQI can be used; for high fever with disturbance of consciousness, AGNHP can be used; for systemic inflammatory response syndrome or multiple organ function failure, XBJI is recommended; SMI can be used for immunosuppression; and SFI can be used for shock.
T765 1768-1986 Sentence denotes Furthermore, the reason that TCM works is not only because it inhibits the virus, but also because it might block infection, regulate the immune response, inhibit the inflammatory storm, and promote repair of the body.
T766 1987-2116 Sentence denotes Moreover, the prevention and control measures of COVID-19 have fully reflected the ideology of “preventive treatment of disease”.
T767 2117-2205 Sentence denotes Physicians should pay attention to the reasonable application of CPMs to treat COVID-19.
T768 2206-2282 Sentence denotes Severe patients are prone to septic shock, and liver and kidney dysfunction.
T769 2283-2371 Sentence denotes In patients with related underlying diseases, drug metabolism and clearance are reduced.
T770 2372-2488 Sentence denotes Treatment options: hepato-renal toxic drugs should be avoided to reduce the risk of drug accumulation and poisoning.
T771 2489-2579 Sentence denotes For example, AGNHP contains cinnabar and realgar, and should not be taken for a long time.
T772 2580-2645 Sentence denotes People with liver and kidney dysfunction should use with caution.
T773 2646-2892 Sentence denotes TRQI should be carefully selected because it aggravates liver and kidney function; LHQWC and JHQGG contain ephedrae herba (Mahuang), and doctors need to monitor patients’ blood pressure, heart condition and combined use of antihypertensive drugs.
T774 2893-3083 Sentence denotes In clinical application of XBJI, SFI and other traditional Chinese medicine injections, attention should be paid to the choice of solvent and the interval between infusions with other drugs.
T775 3084-3162 Sentence denotes As is well known, clinicians use CPMs under the guidance of the theory of TCM.
T776 3163-3350 Sentence denotes Foreign doctors and patients wishing to use CPMs to treat COVID-19 should exercise caution, especially in countries where they may be used incorrectly without the knowledge of TCM theory.
T777 3351-3396 Sentence denotes There are some limitations within this paper.
T778 3397-3679 Sentence denotes First, as there is little direct clinical evidence for the prevention of COVID-19, the reported studies are from previous reports on the prevention of SARS, MERS, H7N9, and H1N1 influenza by CPMs, which can only be considered as indirect evidence in respect of the current outbreak.
T779 3680-3769 Sentence denotes Secondly, the programs for prevention of COVID-19 were issued shortly after the outbreak.
T780 3770-3972 Sentence denotes Chinese medicine experts suggested CPMs to treat COVID-19 based on their previous experience in the prevention and treatment of similar diseases combined with their initial understanding of the disease.
T781 3973-4134 Sentence denotes The actual effects of these programs need to be verified in clinical application, and updated and improved according to the evidence of new research on COVID-19.
T782 4135-4278 Sentence denotes For future studies, we recommend prospective cohort studies, RCTs or registry studies to evaluate the effect of CPMs in prevention of COVID-19.
T783 4279-4377 Sentence denotes Some clinical trial protocols to treat COVID-19 using the top 10 CPMs are ongoing (see Table 4 ).
T784 4378-4723 Sentence denotes At present, since COVID-19 has not yet been controlled, a series of prospective population studies with rigorous design and large sample should commence with protocol registration, and implementation in a timely manner, to produce reliable evidence for CM prevention of COVID-19 or similar emerging respiratory infectious diseases in the future.
T785 4724-4835 Sentence denotes Table 4 Registration information on clinical trial protocols for the top 10 CPMS in the treatment of COVID-19.
T786 4836-4925 Sentence denotes CPMS Registration Number Registration Date Clinical research unit  Registration title
T787 4926-5119 Sentence denotes XYPJ ChiCTR2000029756 2020/2/12 Renmin Hospital of Wuhan University (Wuhan, China) Clinical study of nebulized Xiyanping injection in the treatment of novel coronavirus pneumonia (COVID-19)
T788 5120-5412 Sentence denotes ChiCTR2000030117 2020/2/23 Jiangxi Qingfeng Pharmaceutical Co., Ltd. (Ganzhou, China) A multicenter, randomized, open, parallel controlled trial for the evaluation of the effectiveness and safety of Xiyanping injection in the treatment of common type novel coronavirus pneumonia (COVID-19)
T789 5413-5542 Sentence denotes ChiCTR2000030218 2020/2/25 Fifth People’s Hospital of Ganzhou (Ganzhou, China) Study of Pinavir/Ritonavir tablets (Trade Name:
T790 5543-5628 Sentence denotes Kelizhi) Combined with Xiyanping injection for novel coronavirus pneumonia (COVID-19)
T791 5629-5916 Sentence denotes LHQWC ChiCTR2000029433 2020/2/1 Hebei Yiling Hospital (Shijiazhuang, China), Renmin Hospital of Wuhan University (Wuhan, China) A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule/granule in the treatment of suspected novel coronavirus pneumonia (COVID-19)
T792 5917-6187 Sentence denotes ChiCTR2000029434 2020/2/1 Hebei Yiling Hospital (Shijiazhuang, China), Renmin Hospital of Wuhan University (Wuhan, China) A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule/granule in the treatment of novel coronavirus pneumonia (COVID-19)
T793 6188-6469 Sentence denotes TRQI ChiCTR2000029432 2020/2/1 The First Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangzhou, China) A real world study for the efficacy and safety of large dose Tanreqing injection in the treatment of patients with novel coronavirus pneumonia (COVID-19)
T794 6470-6653 Sentence denotes ChiCTR2000029813 2020/2/14 Shanghai Public Health Clinical Center (Shanghai, China) Clinical trial for Tanreqing capsules in the treatment of novel coronavirus pneumonia (COVID-19)
T795 6654-6887 Sentence denotes XBJI ChiCTR2000029381 2020/1/27 The First Affiliated Hospital of Guangzhou Medical University (Guangzhou, China) A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel coronavirus pneumonia (COVID-19)
T796 6888-7087 Sentence denotes ChiCTR2000030388 2020/3/1 Jingzhou First People’s Hospital (Jingzhou, China) Efficacy and safety of Xue-Bi-Jing injection in the treatment of severe cases of novel coronavirus pneumonia (COVID-19)
T797 7088-7315 Sentence denotes SFJDC ChiCTR2000030043 2020/2/21 Peking University Third Hospital (Beijing, China) Shen-Fu injection in the treatment of severe novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial